Quanterix Scientist Blog Series

Protected: Longitudinal Blood-Based Biomarker Monitoring in Multiple Sclerosis: Why Nf-L and GFAP Matter

There is no excerpt because this is a protected post.

Part 2 – Multimodal Diagnostics: Integrating tissue and blood biopsies

Realizing the promise of multimodal diagnostics raises important questions: How should we think about integrating these different sources of information? Where can multimodal approaches add the most value? And what…

Part 1 – Multimodal Diagnostics: Integrating tissue and blood biopsies

Disease is complex, dynamic, and heterogeneous, and no one biomarker modality can capture every dimension of that complexity. Liquid and tissue biomarkers answer different biological questions, each providing a distinct…

Mapping the Tumor Immune Microenvironment: Spatial Biology Insights into Immunotherapy Response in NSCLC

Lung cancer is a formidable foe. Globally, it is the leading cause of cancer-related deaths in men and women, with non-small lung cancer (NSCLC) representing more than 80% of all…

Synaptic Dysfunction and Neuroinflammation: Complementary Pathways Driving Cognitive Decline 

Accelerator Laboratory Services: The Biomarker Powerhouse 

Proteomics in Transition: From Discovery to Diagnostic Utility

The promise of proteomics lies in its ability to illuminate disease biology at scale, transform translational research, and guide the development of precision diagnostics and targeted therapies. While genomic technologies…

Built for Translation: Why Simoa Stands Alone in Clinical-Grade Biomarker Measurement 

Translating proteomic discovery into clinical action requires more than scale, it demands precision, reproducibility, and quantitative clarity. The Quanterix Simoa® digital immunoassay technology was purpose-built to meet the demands of…